Journal Basic Info

  • Impact Factor: 1.995**
  • H-Index: 8
  • ISSN: 2474-1647
  • DOI: 10.25107/2474-1647
**Impact Factor calculated based on Google Scholar Citations. Please contact us for any more details.

Major Scope

  •  Otolaryngology - Head and Neck Surgery
  •  Thoracic Surgery
  •  Oral and Maxillofacial Surgery
  •  Colon and Rectal Surgery
  •  Bariatric Surgery
  •  Orthopaedic Surgery
  •  Transplant Surgery
  •  Emergency Surgery

Abstract

Citation: Clin Surg. 2022;7(1):3430.Research Article | Open Access

Symptom Palliation by PIPAC for Peritoneal Carcinomatosis from the Gastrointestinal Tract

Frédéric Dumont1*, Jean-Luc Raoul2, Marie-Françoise Heymann3, Judith Raimbourg2, François-Xavier Piloquet4, Cecile Loaec1, Charlotte Bourgin1, Sandrine Hiret2, Hélène Senellart2, Olivier Kerdraon3 and Emilie Thibaudeau1

1Department of Surgical Oncology, Comprehensive Cancer Center, West Cancer Institute, France
2Department of Medical Oncology, Comprehensive Cancer Center, West Cancer Institute, France
3Department of Pathology, Comprehensive Cancer Center, West Cancer Institute, France
4Department of Palliative and Supportive Care, Comprehensive Cancer Center, West Cancer Institute, France

*Correspondance to: Frédéric Dumont 

 PDF  Full Text DOI: 10.25107/2474-1647.3430

Abstract

Background: PIPAC is an innovative palliative care treatment for Peritoneal Carcinomatosis (PC). The purpose of this study is to assess the impact of PIPAC with oxaliplatin on symptoms (occlusion, ascites) of peritoneal metastasis from gastrointestinal tract cancer with assessment of early markers of tumor response. Methods: All consecutive PIPAC with oxaliplatin per formed in a comprehensive cancer center between 2017 to 2020 were included. Cox analysis was used to identify time to Worsening of Symptoms (TWS) factors. Results: 25 patients underwent 85 PIPAC (Median period: 105 days). The primary was colorectal, gastric, and small bowel cancer in respectively 13, 10, and 2 cases. The median TWS and Overall Survivals (OS) after the first PIPAC were respectively 207 and 309 days. No early markers of tumor response (lower PCI or histological grading during PIPAC) were associated with TWS. In univariate analysis, TWS factors were extended PC (PCI>20, p=0.03) and presence of symptoms at first PIPAC (p=0.03). In multivariate analysis, these factors did not reach significance. TWS was particularly short (<3 months) for patients with obstructions. Conclusion: PIPAC with oxaliplatin provides prolonged control of carcinomatosis-related symptoms but seems poorly effective to control pre-existing PC obstructions. No predictive factors extending TWS were identified.

Keywords

Peritoneal carcinomatosis; PIPAC; Oxaliplatin; Symptom; Obstruction; Palliative care

Cite the article

Dumont F, Raoul J-L, Heymann M-F, Raimbourg J, Piloquet F-X, Loaec C, et al. Symptom Palliation by PIPAC for Peritoneal Carcinomatosis from the Gastrointestinal Tract. Clin Surg. 2022; 7: 3430..

Search Our Journal

Journal Indexed In

Articles in PubMed

Monitoring an Ongoing Enhanced Recovery after Surgery (ERAS) Program: Adherence Improves Clinical Outcomes in a Comparison of Three Thousand Colorectal Cases
 PubMed  PMC  PDF  Full Text
Antimicrobial Peptides: A Potential Therapeutic Option for Surgical Site Infections
 PubMed  PMC  PDF  Full Text
View More...

Articles with Grants

Comparison of Two Extended Interbody Fusion Techniques in the Treatment of Adjacent Segment Disease after Transforaminal Lumbar Interbody Fusion: Using Cortical Bone Trajectory Screws vs. Traditional Pedicle Screws Combined with a Novel Domino System
 Abstract  PDF  Full Text
The Impact of ?-Blocker on Coronary Flow Reserve in a Case with Coronary Artery Ectasia
 PDF  Full Text
View More...